Advisor Group Holdings, Inc. Galectin Therapeutics Inc Transaction History

Advisor Group Holdings, Inc.

$67.1 Billion
Q3 2025

A detailed history of Advisor Group Holdings, Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,224,724 shares of GALT stock, worth $6.74 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,224,724

Previous 1,265,384 3.21%

Holding current value

$6.74 Million

Previous $2.67 Million 91.79%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$2.09 - $5.37 $84,979 - $218,344	-40,660 Reduced 3.21%	1,224,724 $5.12 Million
Q2 2025 Sep 04, 2025	BUY	$1.25 - $3.29 $93,561 - $246,253	74,849 Added 6.29%	1,265,384 $2.67 Million
Q2 2025 Aug 13, 2025	SELL	$1.25 - $3.29 $41,101 - $108,178	-32,881 Reduced 2.69%	1,190,535 $2.51 Million
Q1 2025 May 12, 2025	BUY	$1.1 - $1.76 $45,453 - $72,724	41,321 Added 3.5%	1,223,416 $1.49 Million
Q4 2024 Jun 06, 2025	SELL	$0.87 - $3.0 $37,306 - $128,643	-42,881 Reduced 3.51%	1,180,535 $1.4 Million
Q3 2024 Nov 13, 2024	BUY	$2.04 - $2.86 $114,444 - $160,446	56,100 Added 4.98%	1,182,095 $3.25 Million
Q2 2024 Aug 13, 2024	SELL	$2.13 - $4.2 $295,750 - $583,170	-138,850 Reduced 10.98%	1,125,995 $2.54 Million
Q1 2024 May 10, 2024	BUY	$1.6 - $2.44 $22,075 - $33,664	13,797 Added 1.1%	1,264,845 $3.02 Million
Q4 2023 Feb 12, 2024	SELL	$1.6 - $2.18 $3.24 Million - $4.41 Million	-2,024,144 Reduced 61.8%	1,251,048 $2.08 Million
Q3 2023 Nov 13, 2023	BUY	$1.38 - $1.97 $2.54 Million - $3.62 Million	1,839,635 Added 128.15%	3,275,192 $6.29 Million
Q2 2023 Aug 10, 2023	BUY	$1.32 - $2.08 $216,212 - $340,697	163,797 Added 12.88%	1,435,557 $2.07 Million
Q1 2023 May 12, 2023	BUY	$1.1 - $2.4 $1,575 - $3,436	1,432 Added 0.11%	1,271,760 $2.67 Million
Q4 2022 Feb 10, 2023	SELL	$1.03 - $1.66 $32,747 - $52,778	-31,794 Reduced 2.44%	1,270,328 $1.44 Million
Q3 2022 Nov 14, 2022	BUY	$1.31 - $2.48 $23,109 - $43,749	17,641 Added 1.37%	1,302,122 $2.12 Million
Q2 2022 Aug 10, 2022	BUY	$1.19 - $1.74 $22,206 - $32,470	18,661 Added 1.47%	1,284,481 $1.68 Million
Q1 2022 May 04, 2022	SELL	$1.61 - $2.31 $13,100 - $18,796	-8,137 Reduced 0.64%	1,265,820 $2.04 Million
Q3 2021 Nov 05, 2021	BUY	$2.59 - $4.15 $2,072 - $3,320	800 Added 0.06%	1,273,957 $4.94 Million
Q2 2021 Aug 02, 2021	BUY	$2.07 - $5.1 $105,928 - $260,982	51,173 Added 4.19%	1,273,157 $4.07 Million
Q1 2021 May 13, 2021	BUY	$1.96 - $2.57 $246,977 - $323,843	126,009 Added 11.5%	1,221,984 $2.65 Million
Q4 2020 Feb 10, 2021	BUY	$2.24 - $2.87 $134,744 - $172,641	60,154 Added 5.81%	1,095,975 $2.45 Million
Q3 2020 Nov 12, 2020	BUY	$2.53 - $3.64 $59,179 - $85,143	23,391 Added 2.31%	1,035,821 $2.77 Million
Q2 2020 Aug 14, 2020	BUY	$1.66 - $3.15 $245,937 - $466,688	148,155 Added 17.14%	1,012,430 $3.1 Million
Q1 2020 May 18, 2020	BUY	$1.51 - $3.0 $1.31 Million - $2.59 Million	864,275 New	864,275 $1.69 Million

Others Institutions Holding GALT

# of Institutions

Shares Held

11.1M

Call Options Held

142K

Put Options Held

81.4K

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $327M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Galectin Therapeutics Inc Transaction History